Crossmark

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial

Crossref DOI link: https://doi.org/10.1007/s10067-018-4074-6

Published Online: 2018-04-02

Published Print: 2018-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Durez, Patrick https://orcid.org/0000-0002-7156-2356
Pavelka, Karel

Lazaro, Maria Alicia

Garcia-Kutzbach, Abraham

Moots, Robert J.

Amital, Howard

Govoni, Marinella

Vastesaeger, Nathan
Funding

Funding for this research was provided by:

MSD
License Information

Text and Data Mining valid from 2018-04-02
More Information

Article History

Received: 7 November 2017

Revised: 19 February 2018

Accepted: 21 March 2018

First Online: 2 April 2018

Change Date: 12 May 2018

Change Type: Correction

Change Details: The original publication contains two areas which require correcting. None of these errors change the results or conclusions of the article, but the authors wish to highlight the areas of change to the reader.

Compliance with ethical standards

:

: P.D. received fees for participation in speakers’ bureaus for Bristol-Myers Squibb, Samsung, Pfizer, UCB, Mundipharma, Hospira, and Eli Lilly. K.P. received honoraria for speaking and consultations from AbbVie, Pfizer, Roche, Egis, Bristol-Myers Squibb, and MSD. M.D. and N.V. are employees of MSD. All other authors declare no conflict of interest.